VIPAS39

Chr 14AR

VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 homolog

The VIPAS39 protein functions in endosome to lysosome transport and vesicle tethering, playing a critical role in intracellular trafficking and maintaining cellular polarity in epithelial cells. Mutations cause arthrogryposis, renal dysfunction, and cholestasis 2, a multisystem disorder affecting joints, kidneys, and liver function. This condition follows autosomal recessive inheritance.

OMIMResearchSummary from RefSeq, OMIM, UniProt
LOFmechanismARLOEUF 0.801 OMIM phenotype
Clinical SummaryVIPAS39
🧬
Gene-Disease Validity (ClinGen)
arthrogryposis, renal dysfunction, and cholestasis 2 · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.80LOEUF
pLI 0.000
Z-score 2.54
OE 0.55 (0.390.80)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.86Z-score
OE missense 0.85 (0.770.95)
229 obs / 268.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.55 (0.390.80)
00.351.4
Missense OE0.85 (0.770.95)
00.61.4
Synonymous OE0.89
01.21.6
LoF obs/exp: 21 / 37.9Missense obs/exp: 229 / 268.6Syn Z: 0.86

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

VIPAS39 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →